



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61B 19/00	A1	(11) International Publication Number: WO 97/42900 (43) International Publication Date: 20 November 1997 (20.11.97)
<p>(21) International Application Number: PCT/US97/08282</p> <p>(22) International Filing Date: 15 May 1997 (15.05.97)</p> <p>(30) Priority Data: 08/648,561 16 May 1996 (16.05.96) US</p> <p>(60) Parent Application or Grant (63) Related by Continuation US 08/648,561 (CIP) Filed on 16 May 1996 (16.05.96)</p> <p>(71) Applicant (for all designated States except US): THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK [US/US]; West 116th Street and Broadway, New York, NY 10027 (US).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): ROSE, Eric [US/US]; 96 Oxford Drive, Tenafly, NJ 07670 (US). STERN, David [US/US]; 63 Tanners Road, Great Neck, NY 11020 (US). SCHMIDT, Ann, Marie [US/US]; 242 Haven Road, Franklin Lakes, NJ 07417 (US). SPANIER, Talia [US/US]; Apartment 4-C, 600 West 111th Street, New York, NY 10025 (US).</p>	<p>(74) Agent: WHITE, John, P.; Cooper & Dunham LLP, 1185 Avenue of the Americas, New York, NY 10036 (US).</p> <p>(81) Designated States: AU, CA, JP, MX, US, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).</p> <p>Published <i>With international search report.</i></p>	
<p>(54) Title: METHOD FOR INHIBITING THROMBOSIS IN A PATIENT WHOSE BLOOD IS SUBJECTED TO EXTRACORPOREAL CIRCULATION</p> <p>(57) Abstract</p> <p>This invention provides a method for inhibiting thrombosis in a patient whose blood is subjected to extracorporeal blood circulation which comprises contacting the extracorporeal circulating blood with a Factor IXa compound in an amount effective to inhibit thrombosis in the patient. The Factor IXa compound may include an active site-blocked Factor IXa compound or Glu-Gly-Arg chloromethyl ketone-inactivated human factor IXa compound. This invention also provides that the effective amount may be from about 0.1 µg/ml plasma to about 250 µg/ml plasma or from about 0.5 µg/ml plasma to about 25 µg/ml plasma. The patient may be subjected to extracorporeal blood circulation during transplant surgery or cardiopulmonary bypass surgery. This invention further provides for a pharmaceutical composition which includes an effective amount of a Factor IXa compound and a pharmaceutically acceptable carrier.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

**METHOD FOR INHIBITING THROMBOSIS IN A PATIENT WHOSE BLOOD IS
SUBJECTED TO EXTRACORPOREAL CIRCULATION**

5 This application is a continuation-in-part of United States Application Serial No. 08/648,561, filed May 16, 1996 the contents of which are incorporated by reference in its entirety into the present application.

10 **Background of the Invention**

Throughout this application, various publications are referenced by author and date. Full citations for these publications may be found listed alphabetically at the end of the specification
15 immediately preceding the claims. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art as known to those skilled therein as of the date of the invention described and claimed herein.

20

In cardiopulmonary bypass surgery, one of the critical requirements is the maintenance of blood fluidity and the absence of thrombosis. The cardiopulmonary bypass circuit presents a unique combination of factors favoring the development of a
25 prothrombotic environment. The contact of blood with numerous devices which are associated with this procedure, such as membrane oxygenators and filters, has been implicated in the activation of the intrinsic (contact) pathway of coagulation. Since the bypass circuitry generates a highly-thrombogenic environment, high levels
30 of anticoagulation therapies are required (Edmunds, 1995; Edmunds, 1993; Gravlee et al., 1990; Walenga et al., 1991; DeAnda et al., 1994; Brister et al., 1994; and Chomiak et al., 1993). Traditional intervention to prevent thrombosis in this setting has been the use of heparin. However, the use of heparin causes
35 unacceptable side effects in certain patients. Such side effects may include the development of bleeding, heparin resistance or

-2-

arterial/venous thrombosis. Despite investigations which have attempted to provide alternatives to the use of heparin, such as thrombin inhibitors (such as hirudin) and dermatan sulfate, no agent has yet been identified to replace or modify its use in
5 clinical cardiac surgery (Walenga et al., 1991; DeAnda et al., 1994; Brister et al., 1994; and Chomiak et al., 1993).

Summary of the Invention

This invention provides a method for inhibiting thrombosis in a patient whose blood is subjected to extracorporeal blood circulation which comprises contacting the extracorporeal circulating blood with a Factor IXa compound in an amount effective to inhibit thrombosis in the patient. The Factor IXa compound may include an active site-blocked Factor IXa compound or Glu-Gly-Arg chloromethyl ketone-inactivated human factor IXa compound. This invention also provides that the effective amount may be from about 0.1 $\mu\text{g/ml}$ plasma to about 250 $\mu\text{g/ml}$ plasma or from about 0.5 $\mu\text{g/ml}$ plasma to about 25 $\mu\text{g/ml}$ plasma. The patient may be subjected to extracorporeal blood circulation during transplant surgery or cardiopulmonary bypass surgery. This invention further provides for a pharmaceutical composition which includes an effective amount of a Factor IXa compound and a pharmaceutically acceptable carrier.

Brief Description of the Figures

Figure 1. Blood Loss: Factor IXai vs Heparin

Blood loss in the thoracic cavity was assessed in dogs treated with Factor IXai and dogs treated with heparin. After 1 hour of bypass followed by up to three hours of postoperative observation, blood loss was significantly less in the group receiving Factor IXai compared with the group receiving heparin (**, $p < 0.05$).

Figures 2A, 2B, 2C, 2D, 2E and 2F. Scanning Electron Microscopic Analysis of Arterial Filter in Factor IXai vs Heparin

Scanning electron microscopic analysis of the arterial filters is depicted. The Figures 2A, 2C and 2E show serial magnification of the arterial filters in Factor IXai treated dogs (50 x (top), 200x (middle), 2000x (bottom)). The Figures 2B, 2D and 2F show similar views of the heparin treated dogs. As demonstrated in these pictures, cardiopulmonary bypass performed with Factor IXai was associated with similar amounts of clinically inapparent fibrin deposition compared with the use of traditional heparin.

Figures 3A, 3B, 3C, 3D, 3E, 3F 3G, and 3H. Histologic Examination of End Organs

Hematoxylin/eosin staining of heart, lung, kidney, and liver in dogs treated with Factor IXai are shown in Figures 3A, 3C, 3E, 3G. Figures 3B, 3D, 3F and 3H show samples evaluated in dogs treated with heparin. These studies reveal the absence of fibrin deposition and micro emboli in both groups.

Figures 4A, 4B, 4C, 4D and 4E. Analysis of Blood Samples in Dogs Treated with Factor IXai and Heparin

Blood samples were drawn at intervals throughout the surgical procedure and evaluated. Similar dilutional decreases in white blood cells, hematocrit, and platelet count were observed in each group. Levels of prothrombin time and partial thromboplastin time remained baseline in Factor IXai treated dogs while there was

-5-

significant elevation in dogs anticoagulated with heparin. (**p<0.05) {closed diamonds represent Factor IXai; open squares represent heparin}.

5 **Figures 5A and 5B. Factor IX based Clotting Assay.**

A clotting assay was developed to rapidly and reproducibly assess the level of anticoagulation during cardiopulmonary bypass. As shown, this is an assay based on Factor IX deficient plasma and an optimized dose of cephalin to determine the functional
10 anticoagulant effect of Factor IXai.

Figures 6A and 6B. Blood Loss and Hemostasis.

Active Site-blocked Factor IXa was used in peripheral vascular surgery in rabbits and dogs. The blood loss at the aortotomy
15 suture site was substantially less and the time to achieve hemostasis was decreased in animals treated with Factor IXa.

Figure 7. Clotting Time vs. Concentration of Factor IXai

By performing a series of dilutions of administered Factor IXai and determining the clotting time, it was determined that the
20 limit of detection of Factor IXai in the assay is 0.4 µg/ml.

Figure 8. Modified Cephalin Clotting Time (MCCT) vs Time

Determination of MCCT after single dose of Factor IXai in canine cardiopulmonary bypass. After a single clinically-effective dose
25 of Factor IXai (460 µg/kg) in canine cardiopulmonary bypass, the MCCT rises to 80 seconds and is maintained at that level through at least 1.5 hrs of cardiopulmonary bypass.

Detailed Description of the Invention

This invention provides for a method for inhibiting thrombosis in a patient whose blood is subjected to extracorporeal blood circulation which includes contacting the extracorporeal circulating blood with a Factor IXa compound in an amount effective to inhibit thrombosis in the patient. The Factor IXa compound may include an active site-blocked Factor IXa compound or a Glu-Gly-Arg chloromethyl ketone-inactivated human factor IXa compound. The effective amount may include from about 0.1 $\mu\text{g/ml}$ plasma to about 250 $\mu\text{g/ml}$ plasma or from about 0.5 $\mu\text{g/ml}$ plasma to about 25 $\mu\text{g/ml}$ plasma or preferably from 0.7 $\mu\text{g/ml}$ plasma to about 5 $\mu\text{g/ml}$ plasma.

This invention further provides that the patient may be subjected to extracorporeal blood circulation during transplant surgery or cardiopulmonary bypass surgery. The patient may be subjected to extracorporeal blood circulation during any kind of cardiac surgery, including bypass grafting, valve replacement, congenital repair heart surgery and heart transplantation. The patient may be a human being. The patient may also be subjected to extracorporeal life support. The patient may be a cardiogenic shock patient. The patient may be undergoing hemodialysis, continuous arterio-venous hemofiltration (CAVH), continuous veno-venous hemofiltration (CVVH), extracorporeal circulatory membrane oxygenation (ECMO), brain surgery, vascular surgery, abdominal surgery, orthopaedic surgery, hip replacement surgery, transplant surgery, or any surgery requiring cardio-pulmonary bypass. The subject may be any patient requiring a mechanical circulatory assistance or ventricle assist device (i.e. LVAD). The subject may be a patient requiring new devices as described in Wickelgren, 1996 such as implantable defibrillators. The subject may also be a patient suffering with symptoms of systemic lupus erythematosus or TTP (thrombotic thrombocytopenic purpura). The subject may also be a patient requiring plasmapheresis.

-7-

One embodiment of the present invention is a pharmaceutical composition which may include an effective amount of a Factor IXa compound and a pharmaceutically acceptable carrier. The carrier may include a diluent. Further, the carrier may include an appropriate adjuvant, a herpes virus, a liposome, a microencapsule, a polymer encapsulated cell or a retroviral vector. The carrier may include an aerosol, intravenous, oral or topical carrier. The Factor IXa compound may be attached to a solid support. The Factor IXa compound may be linked to or bonded to tubing. The tubing may be part of an extracorporeal life support system.

As used herein "thrombosis" encompasses formation, development or presence of a blood clot or a blood coagulation which is located inside of a patient or inside of an extracorporeal life support system which circulates blood of the patient. Thrombosis also encompasses the presence of a thrombus which includes a blood clot occluding a blood vessel or formed in a heart cavity. Thrombosis also encompasses the activation of a plasmatic coagulation system in a patient which includes the production of cross-linked fibrin degradation product, protein C, free protein S, coagulation factor II, immunoglobulin G or albumin in the patient. "Thrombosis" also encompasses the formation of a white thrombus which may be composed of platelets and fibrin and is relatively poor in erythrocytes, a disseminated fibrin deposit thrombus or a red thrombus which may be composed of red cells and fibrin. Thrombosis may also include a thromboembolism which is the blocking of a blood vessel by a thrombus which may have been dislodged from a vein.

Thrombosis may occur in areas of retarded blood flow in the patient, at a site of injury or at an abnormal vessel wall in conjunction with an initiating platelet plug. Initiation of clot formation in response to tissue injury is carried out by the extrinsic pathway of clotting. Formation of a pure red thrombus

- 8 -

in an area of restricted blood flow or in response to an abnormal vessel wall without tissue injury is carried out by the intrinsic pathway. Intrinsic and extrinsic pathways may converge in a final common pathway characterized by the activation of prothrombin to thrombin and the thrombin-catalyzed conversion of fibrinogen to the fibrin clot.

As used herein "a Factor IXa compound" may encompass the following: a Glu-Gly-Arg chloromethyl ketone-inactivated human factor IXa compound, an inactive Christmas factor, a plasma thromboplastin component, a Glu-Ala-Arg chloromethyl ketone-inactivated bovine factor IXa compound, a glutamyl-glycyl-arginyl-Factor IXa compound, a dansyl Glu-Gly-Arg chloromethyl ketone-inactivated bovine factor IXa (IXai), a Factor IXai, a competitive inhibitor of Factor IXa, a peptide mimetic of a Factor IXa compound, a carboxylated Christmas factor, a competitive inhibitor of prothrombinase complex, a des- γ -carboxyl Factor IX compound, a Factor IX compound lacking a calcium-dependent membrane binding function, an inactive Factor IX including only amino acids 1-47, an apoFactor IX compound including amino acids 1-47, Factor IX Bm Kiryu, a Val-313-to-Asp substitution in the catalytic domain of Factor IX, a Gly-311-to-Glu substitution in the catalytic domain of Factor IX, a Gly-311 to Arg-318 deletion mutant of Factor IX, an anti-Factor IXa antibody, an anti-Factor IXa monoclonal or polyclonal antibody. The Factor IXa compound may also include inactive species of Factor IX described in the references provided herein, especially Freedman et al., 1995; Furie and Furie, 1995; Miyata et al., 1994 and Wacey et al., 1994.

A Factor IXa compound may be an active site-blocked Factor IXa and be prepared as described in Experimental Details below. The Factor IXa compound may include a protein, a polypeptide or a peptide mimic. The compound may include at least the minimum number of domains necessary for activity. The domains may include a signal peptide, a propeptide, a Gla-domain rich in γ -

carboxyglutamic acid residues, a short aromatic amino acid stack domain, two epidermal growth factor-like domains and a serine protease domain. The compound may include post-translational modifications including glycosylation, β -hydroxylation of aspartic acid, γ - carboxylation of glutamic acid and propeptide cleavage. The Factor IXa compound may be a concentrate obtained via heparin affinity chromatography or hydrophobic interaction chromatography. The Factor IXa compound may be a genetically engineered and expressed peptide. The Factor IXa compound may be a recombinant Factor IXa compound in which amino acids at the active site, especially at the active serine amino acid site, have been altered to render the recombinant Factor IXa functionally inactive, but still capable of competing with intact, native Factor IXa for cell surface binding.

Another embodiment of the present invention is an assay to monitor antithrombic activity of a Factor IXa compound infused into circulation of a patient which includes: (a) obtaining Factor IXa-deficient plasma; (b) mixing the plasma from step (a) with celite and with plasma from the patient; (c) incubating the mixture with a source of lipid and calcium chloride under conditions suitable for clot formation; and (d) measuring time necessary for clot formation in the incubate, thereby monitoring the antithrombic activity of the Factor IXa compound infused into the circulation of the patient.

Another embodiment of the present invention is a method for evaluating the ability of an agent to inhibit an active site of a Factor IXa compound which includes: (a) contacting the Factor IXa compound with the agent to form a protein complex; (b) incubating the protein complex under conditions suitable for clot formation; (c) measuring time necessary for clot formation in the incubate, and (d) comparing the time measured in step (c) with the time measured in the absence of the agent, thus evaluating the ability of the agent to inhibit the active site of the Factor IXa

-10-

compound.

Another embodiment of the present invention is an agent capable of inhibiting the active site of a Factor IXa compound obtained from the methods described herein. The agent may be a peptide, a peptidomimetic, a nucleic acid or a small molecule. The agent may be an antibody or portion thereof. The antibody may be a monoclonal antibody or a polyclonal antibody. The portion of the antibody may include a Fab.

The present invention provides for a method for inhibiting thrombosis in a patient whose blood is subjected to extracorporeal blood circulation which includes contacting the extracorporeal circulating blood with an agent capable of inhibiting a step in the intrinsic pathway of coagulation in an amount effective to inhibit thrombosis in the patient. The agent may be an active site-blocked Factor XII compound or an active site-blocked Factor XI compound.

One embodiment of the present invention is a peptidomimetic compound having the biological activity of a Factor IXa compound or a Glu-Gly-Arg chloromethyl ketone-inactivated human Factor IXa compound wherein the compound has a bond, a peptide backbone or an amino acid component replaced with a suitable mimic. Examples of unnatural amino acids which may be suitable amino acid mimics include β -alanine, L- α -amino butyric acid, L- γ -amino butyric acid, L- α -amino isobutyric acid, L- ϵ -amino caproic acid, 7-amino heptanoic acid, L-aspartic acid, L-glutamic acid, cysteine (acetamindomethyl), N- ϵ -Boc-N- α -CBZ-L-lysine, N- ϵ -Boc-N- α -Fmoc-L-lysine, L-methionine sulfone, L-norleucine, L-norvaline, N- α -Boc-N- δ -CBZ-L-ornithine, N- δ -Boc-N- α -CBZ-L-ornithine, Boc-p-nitro-L-phenylalanine, Boc-hydroxyproline, Boc-L-thioprolin. (Blondelle, et al. 1994; Pinilla, et al. 1995).

Also provided by the invention are pharmaceutical compositions

-11-

comprising therapeutically effective amounts of polypeptide products of the invention together with suitable diluents, preservatives, solubilizers, emulsifiers, adjuvants and/or carriers. An "effective amount" as used herein refers to that amount which provides a therapeutic effect for a given condition and administration regimen. Such compositions are liquids or lyophilized or otherwise dried formulations and include diluents of various buffer content (e.g., Tris-HCl., acetate, phosphate), pH and ionic strength, additives such as albumin or gelatin to prevent absorption to surfaces, detergents (e.g., Tween 20, Tween 80, Pluronic F68, bile acid salts), solubilizing agents (e.g., glycerol, polyethylene glycerol), anti-oxidants (e.g., ascorbic acid, sodium metabisulfite), preservatives (e.g., Thimerosal, benzyl alcohol, parabens), bulking substances or tonicity modifiers (e.g., lactose, mannitol), covalent attachment of polymers such as polyethylene glycol to the protein, complexation with metal ions, or incorporation of the material into or onto particulate preparations of polymeric compounds such as polylactic acid, polyglycolic acid, hydrogels, etc, or onto liposomes, microemulsions, micelles, unilamellar or multilamellar vesicles, erythrocyte ghosts, or spheroplasts. Such compositions will influence the physical state, solubility, stability, rate of *in vivo* release, and rate of *in vivo* clearance. The choice of compositions will depend on the physical and chemical properties of the protein having the activity of a Factor IXa compound. For example, a product which includes a controlled or sustained release composition may include formulation in lipophilic depots (e.g., fatty acids, waxes, oils). Also comprehended by the invention are particulate compositions coated with polymers (e.g., poloxamers or poloxamines) and the compound coupled to antibodies directed against tissue-specific receptors, ligands or antigens or coupled to ligands of tissue-specific receptors. Other embodiments of the compositions of the invention incorporate particulate forms protective coatings, protease inhibitors or permeation enhancers for various routes of administration,

-12-

including parenteral, pulmonary, nasal, oral, injection or infusion by intravenous, intraperitoneal, intracerebral, intramuscular, intraocular, intraarterial or intralesional.

5 The present invention incorporates U.S. Patent Nos. 5,446,128, 5,422,426 and 5,440,013 in their entireties as references which disclose the synthesis of peptidomimetic compounds and methods related thereto. The compounds of the present invention may be synthesized using these methods. The present invention provides
10 for peptidomimetic compounds which have substantially the same three-dimensional structure as those compounds described herein.

In addition to the compounds disclosed herein having naturally-occurring amino acids with peptide or unnatural linkages, the
15 present invention also provides for other structurally similar compounds such as polypeptide analogs with unnatural amino acids in the compound. Such compounds may be readily synthesized on a peptide synthesizer available from vendors such as Applied Biosystems, Dupont and Millipore.

20 As used herein, the term "pharmaceutically acceptable carrier" encompasses any of the standard pharmaceutically accepted carriers, such as phosphate buffered saline solution, water, emulsions such as an oil/water emulsion or a triglyceride
25 emulsion, various types of wetting agents, tablets, coated tablets and capsules. An example of an acceptable triglyceride emulsion useful in intravenous and intraperitoneal administration of the compounds is the triglyceride emulsion commercially known as Intralipid®.

30 Typically such carriers contain excipients such as starch, milk, sugar, certain types of clay, gelatin, stearic acid, talc, vegetable fats or oils, gums, glycols, or other known excipients. Such carriers may also include flavor and color additives or other
35 ingredients.

When administered, compounds are often cleared rapidly from the circulation and may therefore elicit relatively short-lived pharmacological activity. Consequently, frequent injections of relatively large doses of bioactive compounds may be required to sustain therapeutic efficacy. Compounds modified by the covalent attachment of water-soluble polymers such as polyethylene glycol, copolymers of polyethylene glycol and polypropylene glycol, carboxymethyl cellulose, dextran, polyvinyl alcohol, polyvinylpyrrolidone or polyproline are known to exhibit substantially longer half-lives in blood following intravenous injection than do the corresponding unmodified compounds (Abuchowski et al., 1981; Newmark et al., 1982; and Katre et al., 1987). Such modifications may also increase the compound's solubility in aqueous solution, eliminate aggregation, enhance the physical and chemical stability of the compound, and greatly reduce the immunogenicity and reactivity of the compound. As a result, the desired *in vivo* biological activity may be achieved by the administration of such polymer-compound adducts less frequently or in lower doses than with the unmodified compound.

Attachment of polyethylene glycol (PEG) to compounds is particularly useful because PEG has very low toxicity in mammals (Carpenter et al., 1971). For example, a PEG adduct of adenosine deaminase was approved in the United States for use in humans for the treatment of severe combined immunodeficiency syndrome. A second advantage afforded by the conjugation of PEG is that of effectively reducing the immunogenicity and antigenicity of heterologous compounds. For example, a PEG adduct of a human protein might be useful for the treatment of disease in other mammalian species without the risk of triggering a severe immune response. The compound of the present invention capable of alleviating symptoms of a cognitive disorder of memory or learning may be delivered in a microencapsulation device so as to reduce or prevent an host immune response against the compound or against cells which may produce the compound. The compound of the

-14-

present invention may also be delivered microencapsulated in a membrane, such as a liposome.

5 Polymers such as PEG may be conveniently attached to one or more reactive amino acid residues in a protein such as the alpha-amino group of the amino terminal amino acid, the epsilon amino groups of lysine side chains, the sulfhydryl groups of cysteine side chains, the carboxyl groups of aspartyl and glutamyl side chains, the alpha-carboxyl group of the carboxy-terminal amino acid, 10 tyrosine side chains, or to activated derivatives of glycosyl chains attached to certain asparagine, serine or threonine residues.

15 Numerous activated forms of PEG suitable for direct reaction with proteins have been described. Useful PEG reagents for reaction with protein amino groups include active esters of carboxylic acid or carbonate derivatives, particularly those in which the leaving groups are N-hydroxysuccinimide, p-nitrophenol, imidazole or 1-hydroxy-2-nitrobenzene-4-sulfonate. PEG derivatives containing 20 maleimido or haloacetyl groups are useful reagents for the modification of protein free sulfhydryl groups. Likewise, PEG reagents containing amino hydrazine or hydrazide groups are useful for reaction with aldehydes generated by periodate oxidation of carbohydrate groups in proteins.

25 This invention is illustrated in the Experimental Detail section which follows. These sections are set forth to aid in an understanding of the invention but are not intended to, and should not be construed to, limit in any way the invention as set forth 30 in the claims which follow thereafter.

EXPERIMENTAL DETAILS

Selective inhibition of the intrinsic pathway of coagulation is one possible way to avoid the use of heparin in extracorporeal circulation. Leaving intact the tissue factor-mediated extrinsic pathway of coagulation (initiated by tissue factor-VIIa) may obviate both adverse bleeding and potential prothrombotic side effects of heparin. These side effects are found in certain sensitized patients such as patients with heparin-induced thrombocytopenia. In these cases, heparin may be associated with a prothrombotic situation.

The coagulation Factor IX/IXa is a single chain vitamin K-dependent coagulation protein. Limited proteolysis of Factor IX results in a cleavage product which is a two-chain serine protease, Factor IXa, which requires association with the cell surface and the cofactor VIIIa in order to express and exhibit procoagulant activity (Gurewich et al., 1979; Gitel et al., 1977; and Benedict et al., 1991). Factor IXa has an important role in coagulation. When clotting is triggered in the intravascular space, (i.e., thrombosis), it is initiated in the presence of low amounts of tissue factor. In this case, Factor IX becomes preferentially activated to Factor IXa, which then feeds into the rest of the procoagulant cascade, leading to fibrin formation. In contrast, activation of Factor X by tissue factor is less favored by at least an order of magnitude under these conditions. Extravascular coagulation, especially protective hemostasis, occurs in the presence of large amounts of tissue factor on mesenchymal cells and the role of Factor IXa is much less important when direct activation of Factor X occurs. Factor IXa is essentially bypassed. Thus, it may be hypothesized that inhibition of Factor IXa participation in coagulation could provide a selective means of anticoagulation by inhibiting intravascular thrombosis without impairing extravascular hemostasis.

-16-

Studies have shown rapid clearance of Factor IX from the intravascular space, the association of infused and endogenous Factor IX with the vessel wall (Thompson, 1986 and Stern et al., 1987) and in vitro studies have demonstrated Factor IX binding to endothelium and platelets. (Heimark and Schwartz, 1983; Stern et al., 1983; and Ahmad et al., 1989) Studies have been performed to characterize the molecular basis of this coagulation protein-cell surface interaction. At the level of the ligand, the amino-terminal gamma-carboxyglutamic acid-containing domain of Factor IX has been shown to be essential for cell surface binding (Toomey et al., 1992; Astermark et al., 1991; Derian et al., 1989; and Ryan et al., 1989). At the level of the cell surface site, previous studies have demonstrated that Factor IX binding involves a protease-sensitive polypeptide. This polypeptide in endothelial cell studies appears to have an Mr=150 kDa (Rimon et al., 1987) and on platelets appears to have an Mr=250 kDa (London and Walsh, 1992).

Factor IXa may be capable of binding to cellular interaction sites in the vessel wall. It is possible that such sites may be a target for therapeutic intervention in certain thrombotic disorders such as cardiopulmonary bypass.

Studies have demonstrated that Factor IX/IXa may contribute to thrombosis. It was found that Factor IXa resulted in formation of thrombi (Gurewich et al., 1979) and that Factor IXa has potent thrombogenic properties in the Wessler stasis model of thrombosis (Gitel et al., 1977). Factor IXa participates in procoagulant pathways as a component of the Factor IXa-VIIIa-X activation complex (intrinsic pathway of coagulation). Multiple studies in vitro demonstrated that use of active site-blocked IXa (dansyl-glutamyl-glycyl-arginyl Factor IXa, or IXai) prevented the assembly of IXa into this critical complex (Chomiak et al., 1993; Thompson, 1986; Lollar and Fass, 1984; Stern et al., 1985; and Ahmad et al., 1989). Studies have demonstrated the functionally-

-17-

active site of Factor IXa (Astermark et al., 1992 and Ahmad et al., 1992). A role for active site-blocked Factor IXa (Factor IXai) has been demonstrated in preventing coronary artery thrombosis in a canine model in which thrombosis is initiated by the introduction of electric current. Extravascular hemostasis was secured, as no untoward bleeding was detectable in an incisional wound model (Benedict et al., 1991). Therefore, Factor IXai may be an ideal antithrombotic agent for use in cardiopulmonary bypass surgery. Specifically, the extrinsic pathway of coagulation would be unaffected and thus the patient would not be predisposed to excess bleeding. Furthermore, other limiting side effects of heparin would be precluded.

In the studies described below, active site-blocked Factor IXa is shown to be a safe and effective antithrombotic agent in a canine model of coronary artery bypass and surgery. An aortotomy was performed in order to stimulate typical cardiac procedures. Pathways regulating control extravascular hemostasis appeared intact because significantly less bleeding was noted in dogs treated with Factor IXai compared with dogs treated with heparin. Furthermore, model studies of cardiopulmonary bypass utilizing active site-blocked Factor IXa further support the efficacy and safety of the present invention.

MATERIALS AND METHODS

Factor IX/IXa was purified from human plasma according to previously-published methods (Benedict et al., 1991 and Stern et al., 1987) and inactivated using glu-gly-arg-chloromethylketone as described (Benedict et al., 1991 and Lollar and Fass, 1984). Purity of the reagents was then ascertained using SDS-PAGE and standard clotting assays (Benedict et al., 1991 and Lollar and Fass, 1984).

Animal studies

-18-

Cardiopulmonary bypass in dogs (each dog weighing approximately 15 kgs) and baboons (each baboon weighing approximately 11 kgs) (Daly et al., 1988 and Bernabei et al., 1995) was instituted and maintained for one hour with cooling to 32⁰C. An aortotomy was performed in order to simulate cardiac surgery procedures. Animals were then weaned from bypass and blood loss was monitored for up to 3 hours.

Animals received either heparin (at a standard dose of 300 IU/kg and protamine (2 mg/kg) reversal) or active site-blocked Factor IXa (at different doses as indicated below).

Multiple parameters were assessed in all animals (receiving either heparin or Factor IXa) as follows:

1. In order to test for evidence of fibrin deposition in the bypass circuitry, the cardiopulmonary bypass tubing and filters were removed at the end of bypass and subjected to analysis by scanning electron microscopy in order to detect possible evidence of fibrin deposition.
2. After sacrifice of the dogs or the baboons, necropsy was performed and the heart, lungs, liver and kidneys were removed. These organs were fixed in formalin and examined by Hemotoxylin & Eosin staining and immunofluorescence for evidence of clot formation or fibrin deposition as well as for the presence of microemboli.
3. Routine hematologic analysis was performed prior to initiation of cardiopulmonary bypass and at every 30 minute interval during the cardiopulmonary bypass in order to determine hemoglobin levels, hematocrit levels, levels of platelets and fibrinogen, white blood cell count, prothrombin time, activated partial thromboplastin time and activated clotting time.

-19-

4. Continuous hemodynamic measurements were performed prior to, during and for up to 3 hours after the institution of cardiopulmonary bypass.
5. Blood loss was quantitated in the thoracic cavity by collecting all blood in the area during the cardiopulmonary bypass itself and for up to three hours after completion of cardiopulmonary bypass.
6. The extent of activation of coagulation in this model was determined in order to determine the contribution of thrombin generation and fibrinolysis, which occurs in the setting of treatment with heparin, and the contribution of Factor IXai to coagulation. For the canine studies, measurement of thrombin-anti-thrombin complex (or TAT, commercially available from Behring Diagnostics, Boston MA) was utilized as a measure of thrombin generation. This assay was cross-reactive with dog plasma. TAT was measured in animals/group of heparin or Factor IX-ai treated dogs prior to institution of cardiopulmonary bypass/IXai treatment and every 30 minutes during cardiopulmonary bypass and every 60 minutes after cardiopulmonary bypass terminated until the animal was sacrificed at 3 hours. In baboon studies, TAT was measured as described herein and prothrombin fragment 1+2(F₁₊₂; Behring Diagnostics) was measured. This assay cross-reacts with standards obtained from human plasma.
7. Markers of fibrinolysis were assessed to identify the extent to which excess fibrinolysis generated during treatment with heparin likely contributed to increased bleeding. These parameters were directly compared with those obtained in dogs treated with Factor IXai. Levels of d-dimers were assessed at the same time points measured for TAT.

RESULTS

Example 1: Canine model of cardiopulmonary bypass

5 Four dogs were treated with standard doses of heparin (300 IU/kg followed by protamine 2 mg/kg) and five dogs were treated with Factor IXai. In dogs (3 total) treated with 460 μ g/kg (single intravenous infusion just prior to the initiation of
10 cardiopulmonary bypass), there was no evidence of excess pressure in the cardiopulmonary bypass circuit or gross clot formation in the tubing. These results were similar to those observed in the dogs treated with heparin. Similarly, systemic hemodynamic profiles were similar in both groups throughout the procedure
15 suggestive of the absence of clinically-relevant thromboses within the bypass circuitry.

Blood loss in the thoracic cavity was significantly less in the group receiving Factor IXai compared with the dogs receiving
20 heparin (Figure 1). After four hours of observation (one hour during cardiopulmonary bypass itself) and three hours following the termination of cardiopulmonary bypass, dogs receiving Factor IXai accumulated 600 ml of blood within the thoracic cavity. This was in marked contrast to dogs receiving standard doses of heparin
25 in which 1000 ml of blood was quantitated in the thoracic cavity ($p < 0.01$).

Consistent with these data and the hypothesis that selective inhibition of the intrinsic pathway of coagulation would leave
30 unaffected the tissue factor-mediated extrinsic pathway of coagulation, dogs that received Factor IXai were observed to have hemostatic clot along the cut surface of the sternum and in surgical tissue planes. However, the dogs treated with heparin did not have these hemostatic markers.

-21-

In order to detect pathological quantities of deposited fibrin within the bypass circuits, the tubing and filters were immediately removed after cardiopulmonary bypass and analyzed by scanning electron microscopy. As shown in Figure 2, cardiopulmonary bypass performed with Factor IXai resulted in similar amounts of fibrin deposition (left panel) compared with cardiopulmonary bypass performed with the use of traditional heparin (opposite). The amount of fibrin deposition in both cases was clinically-inapparent.

In addition to microscopic examination of the bypass material, organs removed at necropsy were examined by microscopy with Hematoxylin/eosin staining. These studies revealed the absence of fibrin deposition and microemboli in the liver, lungs, kidneys and myocardium as shown in Figure 3.

Analysis of blood samples revealed similar dilutional decreases in hematocrit, platelet count and fibrinogen levels in both groups of animals treated with either Factor IXai or heparin (Figure 4).

As demonstrated in Figure 4, Prothrombin time (PT) remained at about the level of the control in the Factor IXai-treated group (7.9 ± 0.1 sec) and activated Partial thromboplastin time (PTT) was mildly elevated (30.4 ± 11 secs). As expected, heparin-treated dogs had significant elevation of PT and PTT (11.9 ± 0.6 secs and >90 secs, respectively). ACT (Activated clotting time) used in cardiopulmonary bypass to quickly assess the level of anticoagulation with heparin (ideal > 480 secs in human subjects) was >400 secs in the heparin-treated group, but unchanged in the Factor IXai-treated group.

In order to determine the optimal dose of Factor IXai that was necessary to safely prevent thrombosis while securing extravascular hemostasis, different doses of Factor IXai were utilized in the canine model. These data revealed that a dose of

-22-

600 $\mu\text{g}/\text{kg}$ (one dog) produced no evidence of clotting in the bypass circuitry. However, there was evidence of increased bleeding in this group (900 ml of blood in dogs treated with Factor IXai) compared with dogs that received a lower dose (460 $\mu\text{g}/\text{kg}$) of Factor IXai. A third group of dogs (1100 ml of blood in dogs) treated with heparin also had evidence of increased bleeding. These data suggested that the 600 $\mu\text{g}/\text{ml}$ dose of Factor IXai was excessive since the lower dose (at least 460 μg) was successful.

In order to determine the minimal dose of Factor IXai needed to prevent clotting in the bypass circuitry, one dog was treated with Factor IXai at a dose of 300 $\mu\text{g}/\text{kg}$. This experiment demonstrated that there was no evidence of improper clotting of the bypass circuitry. In addition, blood loss in the thoracic cavity was 600 ml of blood compared with 1100 ml of blood in the thoracic cavity of dogs treated with standard doses of heparin.

As indicated above, there was an inability to assess the effectiveness of anticoagulation via measurement of activated clotting time in dogs treated with Factor IXa. Thus, a clotting assay was developed in order to determine the functional effectiveness of Factor IXai rapidly and reproducibly, thereby providing a means to assess the level of anticoagulation frequently during cardiopulmonary bypass. It is necessary to be able to frequently determine the ability of blood of a human patient to coagulate throughout the performance of cardiopulmonary bypass surgery or any majory surgery. The sensitivity of the assay was dependent on the use of Factor IX-deficient plasma and an optimized dose of cephalin (source of phospholipid) as shown in Figure 5. Comparison of plasma from dogs treated with Factor IXai compared with control dog plasma revealed a four-fold increase in clotting time. This assay therefore provided a means of rapidly determining the extent of anticoagulation in animals treated with Factor IXai. Further studies may be performed to determine the desired extent of increased clotting time in this assay in order

-23-

to achieve maximal antithrombotic effects, while maintaining intact the pathways of extravascular hemostasis.

Example 2: Baboon model of cardiopulmonary bypass

5 Studies in baboon models of cardiopulmonary bypass are effective and predictive for future testing of active site-blocked Factor IXa in human subjects. Adequate pre-clinical data in primates is expected to more closely predict expected results in humans. 10 Experiments have been performed in baboons. In one experiment, a baboon received Factor IXai (460 μ g/kg) and a second baboon received heparin/protamine (300 IU/heparin followed by protamine [2 mg/kg]). The data from these trials revealed that there was no evidence of pathologic clotting in the bypass circuitry observed 15 in either group of animals. Similar to the results from the case of dogs treated with Factor IXai, there was evidence of significantly decreased blood loss in the thoracic cavity of baboons treated with Factor IXa (320 ml of blood) compared with baboons treated with standard doses of heparin (600 ml of blood).

20 Preliminary hematologic analysis in the baboons shows that there are similar dilutional decreases in hematocrit, white blood cell counts and platelets as seen in the dog trials. Other studies were completed to investigate the effects of Factor IXai in 25 baboons and to characterize the hemostatic findings.

DISCUSSION

30 The use of heparin has been associated with multiple side effects in certain patients undergoing cardiopulmonary bypass. The side effects include excessive bleeding (at least in part due to excess fibrinolysis), heparin resistance (potentially requiring use of anti-thrombin III to achieve desired heparin effects), heparin-induced thrombocytopenia (with potential for either excess 35 bleeding or clotting in the arterial and/or venous system) and

-24-

need for reversal with protamine.

5 Data from studies of the canine and baboon models of
cardiopulmonary bypass suggest that in patients in whom heparin is
relatively contraindicated, the use of active site-blocked Factor
IXai as an antithrombotic agent may be useful to prevent
pathologic clotting in the circuitry. This clotting may be
lessened by the inhibition of the intrinsic pathway of
coagulation. However, securing the functional responsiveness of
10 the extrinsic (extravascular) pathway of coagulation is critical
in minimizing excess blood loss due to cut vessels of the sternum,
etc. Furthermore, obviating the use of heparin will be useful to
minimize the excessive fibrinolysis generated by its use at doses
required to maintain an activated clotting time > 480 secs during
15 cardiopulmonary bypass.

The use of Factor IXai has been shown to be a safe means of
inhibition of thrombosis during cardiopulmonary bypass and a range
of other cardiac and surgical procedures.

20 In canine and baboon cardiopulmonary bypass models, the selective
inhibition of the intrinsic/contact system of coagulation has been
demonstrated. Maintenance of the extrinsic/tissue factor mediated
pathway allows for the successful maintenance of patency of the
cardiopulmonary bypass circuit while allowing extravascular
25 hemostasis. The possible applications of this therapeutic
intervention extend well beyond the cardiopulmonary bypass
setting.

30 For example, extracorporeal life support with extracorporeal
membrane oxygenation (ECMO) (Magovern, 1995) is being used more
frequently to support adult patients who develop cardiogenic
shock. Studies have demonstrated that this intervention provides
excellent oxygenation and hemodynamic support in this critically
35 ill population. However, the morbidity and mortality associated

with this procedure remains high. Central to the life-threatening complications associated with extracorporeal membrane oxygenation is the unavoidable need for systemic heparinization with its attendant hemorrhagic complications (Muehrcke et al., 1995).
5 Heparin-bonded circuits have provided an alternative to full heparinization with some success, but this model still carries the significant risk of bleeding and thrombosis (Perchinisky et al., 1995 and Atkinson et al., 1992). Selective intravascular anticoagulation with Factor IXai would logically be an ideal
10 alternative to traditional heparinization.

Baboons may be maintained on an extracorporeal membrane oxygenation circuit for up to one week with anticoagulation initiated by Factor IXai, in lieu of heparin. Similarly, active
15 site-blocked Factor IXa may also be useful in any setting requiring the contact of blood with extracorporeal circuitry, such as plasmapheresis, renal hemodialysis, continuous arterio-venous hemofiltration (CAVH), veno-venus hemofiltration (CVVH), extracorporeal circulatory membrane oxygenation (ECMO), brain
20 surgery, vascular surgery, abdominal surgery, transplant surgery, any procedure in which systemic anticoagulation is routinely required, and any procedure in which a patient requires a mechanical circulatory assistance, ventricle assist device, artificial heart, left/right ventricle assist device or a similar
25 biomedical device.

Another potential indication for the use of active site-blocked Factor IXa as an anticoagulant involves the surgical intervention of intracranial aneurysms. Surgery for aneurysm correction must
30 be performed without the use of systematic anticoagulation because the risk of hemorrhagic complications associated with the use of heparin during this procedure are unacceptable. A "watershed" portion of the brain matter immediately adjacent to the aneurysm is therefore sacrificed with the surgical clipping of the aneurysm
35 as tributary vessels thrombose and thus infarct adjacent brain

-26-

tissue. This procedure may be performed with local infusion of Factor IXai to allow intravascular anticoagulation, thus maintaining blood flow through tributaries of the clipped vessel to the brain matter around the aneurysm. Meanwhile, 5 extravascular/tissue factor mediated hemostasis would ensure that a hemorrhagic infarction did not occur. A murine model of stroke may be studied to determine if local infusion of Factor IXai will limit the "watershed" region around a clipped cerebral vessel while preventing hemorrhage.

10 **Example 3: Applications of Active site-blocked Factor IXa (IXai) as an antithrombotic agent in cardiopulmonary bypass**

One of the potential uses of Factor IXai might be in vascular 15 surgery. At the present time, when vascular surgery is performed, a polytetrafluoroethylene (PTFE) graft is used to reconstitute an injured native blood vessel. At the time of surgery, heparin therapy is indicated in order to prevent thrombosis at the site of the graft. One of the consequences of this intervention, however, 20 is increased bleeding at the needle hole sites (where graft connects with the native vessel). This may increase duration of anesthesia since these bleeding sites must be secured and hemostasis confirmed prior to conclusion of the operation. These interventions, by increasing duration of anesthesia, may actually 25 increase morbidity, especially in predisposed patients.

Studies have been performed with a standing protocol in which a graft (PTFE) is created and then tests of the effects of certain interventions are performed on the graft. One intervention, use 30 of Factor IXai, resulted in no evidence of thrombosis and greatly minimized bleeding about the sites of the needle holes. To follow are results of data:

Studies to test the role of Factor IXai as a novel antithrombotic 35 agent in this setting have been performed in a rabbit model of

-27-

vascular repair. An infrarenal abdominal aortotomy was performed and reconstructed with a Polytetrafluoroethylene (PTFE) graft (2X6 mm).

5 **Methods:**

A PTFE graft was placed as above and preweighed gauze pad placed near the needle holes. IXai was administered as an intravenous bolus dose at the time of the graft placement. Time to bleeding was observed and weight of gauze after bleeding ceased determined to quantitate the amount of blood loss:

Results of studies:

15	Factor IXai:	360 microgram/kg:	
		Time to stop bleeding:	3 minutes
20		Weight of gauze after tare:	5.54 grams
	Factor IXai:	260 microgram/kg:	
25		Time to stop bleeding:	3 minutes
		Weight of gauze after tare:	2.09 grams
30	Heparin:	25 U/kg:	
		Time to stop bleeding:	4 minutes
35		Weight of gauze after tare:	8.61 grams

-28-

Even at the lowest effective dose of Factor IXai, there was no evidence of thrombus in the PTFE graft. These results suggest that use of Factor IXai may be beneficial in vascular surgery by preventing thrombosis peri-PTFE graft and, yet, at the same time, securing vascular hemostasis.

Regarding interpretation of the results of the PTFE graft placement in rabbits with either Factor IXai or standard heparin therapy:

The effectiveness of Factor IXai in preventing intravascular thrombosis at the site of PTFE graft placement is dose dependent. At the lowest dose studied to date, 260 microgram/kg of IXai, there is NO evidence of thrombosis in the setting of minimal bleeding complication - which is clearly superior to the bleeding observed using the standard dose of heparin. However, as the dose of Factor IXai approaches 360 microgram/kg, there is similar prevention of thrombosis, but increased bleeding. These data suggest that at higher doses of Factor IXai, the anticoagulant effect is more potent than the selective antithrombotic effect at lower doses (of Factor IXai).

Use of Active Site-blocked Factor IXa (IXai in peripheral vascular surgery).

A. Rabbit aortotomy

To date, 37 rabbits have been completed using the New Zealand rabbit model. 21 rabbits have been treated with Factor IXai 300 microgram/kg and 16 rabbits received standard doses of heparin, in this case (50 U/kg). The results of these studies show that the blood loss at the aortotomy suture site was substantially less in the rabbits treated with Factor IXai vs. heparin:

Factor IXai	2.7±2.5 gms	vs
heparin	6.9±4.4 gms	p<0.05

-29-

Similarly, the time to achieve hemostasis was decreased in animals treated with Factor IXai:

5 Factor IXai 120±38 seconds
 heparin 176±46 seconds p<0.05

(See Figures 6A and 6B).

10 12 rabbits were allowed to survive up to 2 months postoperatively.
Of these, 6 had been treated with Factor IXai for aortotomy/PTFE
graft placement and 6 were treated with heparin. At sacrifice,
100% of the grafts were patent, with no evidence of intimal
hyperplasia by hematoxylin and eosin staining, and no evidence of
15 systemic thrombin generation, as measured by Thrombin-antithrombin
III complex (TAT).

**B. Canine carotid 2x8 mm PTFE patch repair of Right carotid
aortotomy**

20 To date, 14 dogs have undergone this procedure, 7 dogs received
Factor IXai (300 microgram/kg) and 7 dogs received heparin (50
IU/kg). The data demonstrate that there is substantially
decreased blood loss in dogs treated with Factor IXai vs. those
treated with heparin:

25 Factor IXai 20.8±12.9 gms
 heparin 39.1±5.5 gms p<0.05

30 In addition, time to achieve hemostasis was lower in the animals
treated with Factor IXai:

 Factor IXai 162±34 seconds vs
 heparin 228±17 seconds p<0.05

35 See Figures 6A and 6B.

-30-

One of the important concerns in such a model is whether or not the agent increased the incidence of graft occlusion or intimal hyperplasia. Similar to the results obtained in rabbits, ultrasound at one month revealed all grafts to be patent; there were no difference observed in dogs treated with Factor IXai or heparin. Also, serial measurement of TAT revealed that there was no evidence of thrombin generation from one week postoperatively, through two months postoperatively.

II. Modified Cephalin Clotting Time (MCCT)

MCCT has also been characterized.

A. Limit of detection.

By performing a series of dilutions of added Factor IXai and determining the clotting time as otherwise noted in the original application, it has been determined that the limit of detection of Factor IXai in the assay is 0.4 μ g/ml. See Figure 7.

B. Determination of MCCT after single dose of Factor IXai in canine cardiopulmonary bypass.

After a single clinically-effective dose of Factor IXai (460 μ g/kg) in canine CPB, the MCCT rises to 80 secs, and is maintained at the level through at least 1.5 hours of cardiopulmonary bypass (CPB). Post-CPB, MCCT remained elevated through at least 2 hours, and normalized by 3 hours after initiation of CPB. These data suggested that in uncomplicated CPB (at least 1.5 hr), one dose of Factor IXai is likely sufficient. See Figure 8.

Summary: Active-site Blocked Factor IXa (IX ai): A Novel Selective Anticoagulant for Use in Cardiopulmonary Bypass

The use of heparin in cardiopulmonary bypass (CPB) prevents intravascular/extracorporeal circulation thrombosis but also interferes with protective extravascular hemostasis due to its multiple sites of blockade in the coagulation cascade and its

-31-

adverse effect on platelet function. In addition, the presence of heparin-associated antibodies can result in paradoxical thrombosis with severe consequences. Furthermore, protamine reversal may be accompanied by allergy, hemodynamic instability, or pathologic thrombosis. An alternative to heparin would have great clinical implications. The prothrombotic stimuli associated with CPB are complex with early activation likely to occur through activation of the contact (intrinsic) pathway. Later in CPB (>2 hrs), activated monocytes on the bypass circuitry express low levels of tissue factor (TF), resulting in activation of Factor IX by Factor VIIa-TF pathway. The role of Factor IXa (IXa) was studied since it is activated upon stimulation of the contact/intrinsic system; as well as in the presence of low amounts of TF, such as that observed early in CPB or later in CPB with low numbers of activated monocytes on the bypass circuitry. It was hypothesized that blockade of IXa would inhibit intravascular/extracorporeal thrombosis while preserving extravascular hemostasis (where high amounts of Factor VIIa-TF will directly activate Factor X and promote clot formation). A baboon model of CPB was established using active site-blocked IXa, (dansyl-glutamyl, glycyl-arginyl chlormethylketone IXai), a competitive inhibitor of the assembly of IXa in the Factor X activation complex, as an anticoagulant. Standard single-stage CPB was performed in 10 baboons; 6 received IXai (300 to 600 $\mu\text{g/kg}$) /no reversal and 4 received heparin (300 IU/kg) /protamine (2 mg/kg). CPB was maintained for one hour with cooling to 32°C. An aortotomy was performed and repaired. Baboons were weaned from CPB and blood loss monitored for 3 hours postoperatively. At doses from 400 $\mu\text{g/kg}$ to 460 $\mu\text{g/kg}$ systemic hemodynamic profiles were similar in both groups throughout the procedure, with no evidence of excess pressures in the CPB circuit or gross clot formation in the tubing. Scanning electron microscopy of arterial filters revealed no differences in fibrin deposition in the animals treated with IXai vs. those treated with heparin. At necropsy, there was no evidence of pathologic clot formation or bleeding within the abdominal or thoracic cavities

-32-

nor fibrin deposition/microemboli in the heart, lung, liver or kidney in animals treated with IXai or heparin. In contrast to heparin, animals treated with IXai (at doses < 600 $\mu\text{g/kg}$) had hemostatic clot along the cut surface of the sternum and in surgical tissue planes during the entire procedure. Blood samples revealed similar dilutional decreases in hematocrit, platelet count, and fibrinogen levels. Prothrombin time and partial thromboplastin time were only slightly elevated in baboons receiving IXai (13.2 ± 1.2 and 27.1 ± 4.5 , respectively). Similarly, activated clotting time (ACT) was unchanged in the IXai group. In order to rapidly and reproducibly measure the effective antithrombotic level of IXai in plasma, a cephalin-IXa-based clotting assay was developed (modified cephalin clotting time; or MCCT). At 1:32 dilution of cephalin, normal test plasma had clotting time of 21 secs. After a single infusion of IXai (400 to 460 $\mu\text{g/kg}$), MCCT rose to 80 secs and remained at that level for up to 2 hours postoperatively; thereby potentially protecting bypass graft patency into the immediate postoperative period. Taken together, these data suggest that IXai may be a safe and effective alternative anticoagulant for selected patients undergoing CPB, preventing intravascular-extracorporeal circulation thrombosis while preserving extravascular hemostasis.

References

- Ahmad, S., Rawala-Sheikh, R., Ashby, B. And P. Walsh (1989) Platelet receptor-mediated Factor X activation by Factor Ixa: high
5 affinity Factor IX receptors induced by Factor VIII are deficient on platelets in Scott syndrome. *J. Clin. Invest.* **84**:824-828.
- Ahmad, s., Rawalah-Sheik, R. and Walsh, P. Comparative interactions of factor IX and Ixa with human platelets. (1989) *J.*
10 *Biol. Chem.* **264**:3244-3251.
- Ahmad, S.D., Rawala-Sheikh, R., Cheung, W.F., Stafford, D.W., Walsh, P.N. (1992) The role of the first growth factor domain of human factor Ixa in binding to platelets and in factor X
15 activation. *J. Biol. Chem.* **267**(12):8571-6.
- Astermark, J., Bjork, I., Ohlin, A., Stenflo J. (1991) Structural requirements for Ca++ binding to gamma carboxy glutamic acid and epidermal growth factor like regions of FIXa studies using intact
20 domains isolated from controlled proteolytic digests of bovine Factor Ixa. *J. Biol. Chem.* **266**:2430-2437.
- Astermark, J., Hogg, P.J., Bjork, I., Stenflo, J. (1992) Effects of gamma-carboxyglutamic acid and epidermal growth factor-like
25 modules of factor IX on Factor activation. Studies using proteolytic fragments of bovine factor IX. *J. Of Biol. Chem.* **267**(5):3249-56.
- Atkinson, J.B., Kitagawa, H., Humphries, B. (1992) Major surgical
30 intervention during extracorporeal membrane oxygenation. *J. Of Pediatric Surgery* **27**(9):1197-1198.
- Benedict, C., Ryan, J., Wolitzky, B., Ramos, R., Gerlach, M., Tijburg, P., and Stern, D. (1991) Active site-blocked Factor Ixa
35 prevents intranvascular thrombus formation in the coronary

-34-

vasculature without inhibiting extravascular coagulation in a canine thrombosis model. *J. Clin. Invest.* **88**:1760-1765.

Bernabei, A., Gihahis, N., Maione, E.E., Kowalska, M.A., Yan, S.,
5 Niewiarowski, S., Edmunds, L.H., Jr. (1995) Reversal of heparin anticoagulation by recombinant platelet factor 4 and protamine sulfate in baboons during cardiopulmonary bypass. *J. Thorac. & Cardiovasc. Surg.* **109**(4):765-71.

10 Berntorp, E., Björkman, S., Carlsson, M., Lethagen, S. and Nilsson, I.M. (1993) Biochemical and in vivo properties of high purity factor IX concentrates. *Thrombosis and Haemostasis* **70**(5):768-773.

Blondelle et al. (1994).

15 Brister, S.J., Ofosu, F.A., Heigenhauser, G.J.F, Gianese, F., and Buchanan, M.R. (1994) Is heparin the ideal anticoagulant for cardiopulmonary bypass? Dermatan Sulphate may be an alternate choice. *Thrombosis & Haemostasis* **71**:468-473.

20 Chomiak, P.N., Walenga, J.M., Koza, M.J., Reilly, T.M., Turlapathy, P., and Pifarre, R. (1993) Investigation of a thrombin inhibitor peptide as an alternative to heparin in cardiopulmonary bypass surgery. *Circ.* **88**:407-412.

25 Daly, R.C., McCarthy, P.M. Orszulak, T.A., Schaff, H., Edwards, I.D. (1988) Histologic comparison of experimental coronary artery bypass grafts: similarity of in situ and free internal mammary artery grafts. *J. Thorac. & Cardiovasc. Surg.* **96**(1):19-29.

30 DeAnda, A., Coutre, S.E., Moon, M.R., Vial, C.M., Griffin, L.C., Law, V.S., Komeda, M., Leung, L.L.K., and Miller, D.C. (1994) Pilot study of the efficacy of a thrombin inhibitor for use during cardiopulmonary bypass. *Ann. Thorac. Surg.* **58**:344-350.

35

-35-

- Derian, C., VanDusen, W., Przysiecki, C., Walsh PN, Berkner KL, Daufman RJ, Friedman, PA. (1989) Inhibitors of 2-ketoglutarate dependent dioxygenases block aspartyl beta-hydroxylation of recombinant human factor IX in several mammalian expression systems. *Biol. Chem.* **264**:6615-6618.
- Edmunds, L. H. (1993) Blood-surface interactions during cardiopulmonary bypass. *J. Card. Surg.* **8**:404-410.
- Edmunds, L. H. (1995) Why cardiopulmonary bypass makes patients sick: strategies to control the blood-synthetic surface interface. *Adv. In Cardiac Surg.* **6**:131-167.
- Freedman, S.J., Furie, B.C., Furie, B. and Baleja, J.D. (1995) Structure of the metal-free γ -carboxyglutamic acid-rich membrane binding region of factor IX by two-dimensional NMR spectroscopy. *J. Biol. Chem.* **270**(14):7980-7987.
- Furie, B.C. and Furie, B. (1995) Biosynthesis of factor IX: Implications for gene therapy. *Thrombosis and Haemostasis* **74**(1):274-277.
- Gitel, S., Stephenson, R., and Wessler, S. (1977) In vitro and in vivo correlation of clotting protease activity: effect of heparin. *Proc. Natl. Acad. Sci.* **74**:3028-3032.
- Gravlee, G.P., Haddon, W.S., Rothberger, H.K., Mills, S.A., Rogers, A.T., Bean, V.E., Buss, D.H., Prough, D.S., and Cordell, A.R. (1990) Heparin dosing and monitoring for cardiopulmonary bypass. *J. Thorac, Cardiovasc. Surg.* **99**:518-527.
- Gurewich, V., Nonn, T., and Lipinski, B. (1979) Activation of extrinsic or intrinsic blood coagulation in experimental venous thrombosis and disseminated intravascular coagulation: pathogenic differences. *Thromb. Res.* **14**:931-940.

-36-

- Heimark, R., and Schwartz, S. (1983) Binding of coagulation factors IX and X to the endothelial cell surface. *Biochem. Biophys. Res. Commun.* **111**:723-731.
- 5 Iberti, T.J., Miller, M., Ablao, A., Fischer, E.P., Pst, K.D., Benjamin, E., Oropello, J.M., Wiltshire-Clement, M. and Rand, J.H. (1994) Abnormal coagulation profile in brain tumor patients during surgery. *Neurosurgery* **34(3)**:389-395.
- 10 Keating, M.T. and Sanguinetti, M.C. (1996) Molecular genetic insights into cardiovascular disease. *Science* **272**:681-685.
- Kuwabara, K., Pinsky, D.J., Schmidt, A.M., Benedict, C., Brett, J., Ogawa, S., Broekman, M.J., Marcus, A.J., Sciacca, R.R.,
15 Michalak, M., Wang, F., Pan, Y.C., Grunfeld, S., Patton, S., Malinski, T., Stern, D.M. and Ryan, J. (1995) Calreticulin. an antithrombotic agent which binds to vitamin K-dependent coagulation factors, stimulates endothelial nitric oxide production, and limits thrombosis in canine coronary arteries. *J.*
20 *Biol. Chem.* **270(14)**:8179-8187.
- Lollar, P., and Fass, D. (1984) Inhibition of activated porcine Factor IX by dansyl-glutamyl-glycyl-arginyl-chloromethylketone. *Arch. Biochem. Biophys.* **233**:673-682.
- 25 London, F. And P. Walsh. (1992) *Circulation* **86**:(suppl 1), 1855.
- Magovern, G.L. (1995) Treatment with extracorporeal Membrane Oxygenation for Postcardiotomy Cardogenic Shock. *Advances in*
30 *Cardiac Surgery* **6**:169-193.
- Miyata, T., Kuze, K., Matsuse, T., Komooka, H., Kamiya, K., Umeyama, H., Matsui, A., Kato, H., and Yoshioka, A. (1994) Factor IX Bm Kiryu: a Val-313-to-Asp substitution in the catalytic domain
35 results in loss of function due to a conformational change of the

-37-

surface loop: evidence obtained by chimaeric modelling. *British J. of Haematology* **88**:156-165.

- 5 Muehrcke, D.D., McCarthy, P.M., Stewart, R.W., Seshagiri, S., Ogella, D.A., Foster, R.C., Cosgrove, D.M. (1995) Complications of Extracorporeal Life support systems using heparin-bound surfaces: the risk of intracardiac clot formation. *J. Thorac. Cardiovasc. Surg.* **110**:843-51.
- 10 Perchinisky, M.J., Long, W.B., Hill, J.G., Parsons, J.A., Bennett, J.B. (1995) Extracorporeal Cardipulmonary Life Support with heparin bonded circuitry in the resuscitation of massively injured trauma patients. *Am. J. Surg.* **169**:488-491.
- 15 Rimon, S., Melame, R., Savion, N., Scott, T. Nawroth, P.P., Stern, D.M. (1987) Identification of a factor IX/IXa binding protein on endothelial cell surfaces. *J. Biol. Chem.* **262**:6023-6031.
- 20 Ryan, J., Wolitzky, B., Heimer, E., Lambrose, T., Felix, A., Tam, J.P., Huang, L.H., Nawroth, P., Wilner, G., Kisiel, W., Nelsestuen, G.L., and Stern, D.M. (1989) *J. Biol. Chem.* **264**:20283-20287.
- 25 Santagostino, E., Mannucci, P.M., Gringeri, A., Tagariello, G., Baudo, F., Bauer, K.A. and Rosenberg, R.D. (1994) Markers of hypercoagulability in patients with hemophilia B given repeated, large doses of factor IX concentrates during and after surgery. *Thrombosis and Haemostasis* **71(6)**:737-740.
- 30 Stern, D., Drillings, M., Nossel, J., Hurlet-Jensen, A., LaGamma, K., and Owen, J. (1983) Binding of factors IX and Ixa to cultured vascular endothelial cells. *Proc. Natl. Acad. Sci.* **81**:913-917.
- 35 Stern, D., Knotter, G., Kisiel, W., and Nawroth, P. (1987) In vivo evidence of intravascular binding sites for coagulation factor IX.

Br. J. Hematol. **66**:227-232.

Stern, D., Nawroth, P. Kisiel, W., Vehar, G. And Esmon, D. (1985)
The binding of Factor Ixa to cultured bovine endothelial cells:
5 induction of a specific site in the presence of factor VIII and X.
J. Biol. Chem. **260**:6717-6722.

Thompson, A. (1986) Structure, function and molecular defects of
Factor IX. *Blood* **67**:565-572.

10

Toomey, J., Smith, K., and Stafford D. (1991) Localization of
human tissue factor recognition determinants of human factor VIIa.
J. Biol. Chem. **266**:19198-19202.

15

Toomey, J., Smith, K., Roberts, H., Stafford, DW. (1992) The
endothelial binding determinant of human factor IX resides in the
gamma-carboxyglutamic acid domain. *Biochemistry* **31**:1086-1808.

20

Wacey, A.I., Krawczak, M., Kakkar, V.V. and Cooper, D.N. (1994)
Determinants of the factor IX mutational spectrum in haemophilia
B: an analysis of missense mutations using a multi-domain
molecular model of the activated protein. *Hum. Genet.* **94**:594-608.

25

Walenga, J.M., Bakhos, M., Messmore, H.L., Fareed, J., and
Pifarre, R. (1991) Potential use of recombinant hirudin as an
anticoagulant in cardiopulmonary bypass model. *Ann. Thorac. Surg.*
51:271-277.

30

Warrier, I., Kasper, C.K., White II, G.C., Shapiro, A.D., Bergman,
G.E. and The Mononine[®] Study Group (1995) Safety of high doses of
a monoclonal antibody-purified factor IX concentrate. *Am. J. of*
Hematol. **49**:92-94.

35

Wickelgren, I. (1996) New devices are helping transform coronary
care. *Science* **272**:668-670.

What is claimed is:

- 5 1. A method for inhibiting thrombosis in a patient whose blood is subjected to extracorporeal blood circulation which comprises contacting the extracorporeal circulating blood with a Factor IXa compound in an amount effective to inhibit thrombosis in the patient.
- 10 2. The method of claim 1, wherein the Factor IXa compound is an active site-blocked Factor IXa compound.
3. The method of claim 1, wherein the Factor IXa compound is Glu-Gly-Arg chloromethyl ketone-inactivated human factor IXa
15 compound.
4. The method of claim 1, wherein the effective amount comprises from about 0.1 $\mu\text{g/ml}$ plasma to about 250 $\mu\text{g/ml}$ plasma.
- 20 5. The method of claim 1, wherein the effective amount comprises from about 0.5 $\mu\text{g/ml}$ plasma to about 25 $\mu\text{g/ml}$ plasma.
6. The method of claim 1, wherein the effective amount comprises from about 0.7 $\mu\text{g/ml}$ plasma to about 5 $\mu\text{g/ml}$ plasma.
25
7. The method of claim 1, wherein the patient is subjected to extracorporeal blood circulation during transplant surgery, abdominal surgery, vascular surgery or cardiopulmonary bypass surgery.
30
8. The method of claim 1, wherein the patient is a human being.
9. A pharmaceutical composition which comprises an effective amount of a Factor IXa compound and a pharmaceutically acceptable carrier.
35

-40-

10. The pharmaceutical composition of claim 9, wherein the carrier comprises a diluent.

11. The pharmaceutical composition of claim 9, wherein the carrier comprises an appropriate adjuvant, a herpes virus, a liposome, a microencapsule, a polymer encapsulated cell or a retroviral vector.

12. The pharmaceutical composition of claim 9, wherein the carrier is an aerosol, intravenous, oral or topical carrier.

13. An assay to monitor antithrombic activity of a Factor IXa compound infused into circulation of a patient which comprises:

(a) obtaining Factor IXa-deficient plasma;

(b) mixing the plasma from step (a) with celite and with plasma from the patient;

(c) incubating the mixture with a source of lipid and calcium chloride under conditions suitable for clot formation; and

(d) measuring time necessary for clot formation in the incubate, thereby monitoring the antithrombic activity of the Factor IXa compound infused into the circulation of the patient.

14. A method for evaluating the ability of an agent to inhibit an active site of a Factor IXa compound which comprises:

(a) contacting the Factor IXa compound with the agent to form a protein complex;

-41-

(b) incubating the protein complex under conditions suitable for clot formation;

(c) measuring time necessary for clot formation in the incubate, and

(d) comparing the time measured in step (c) with the time measured in the absence of the agent, thus evaluating the ability of the agent to inhibit the active site of the Factor IXa compound.

15. The method of claim 14, wherein the agent comprises a peptide, a peptidomimetic, a nucleic acid or a small molecule.

16. The method of claim 14, wherein the agent is an antibody or portion thereof.

17. The method of claim 16, wherein the antibody is a monoclonal antibody or a polyclonal antibody.

18. The method of claim 16, wherein the portion of the antibody comprises a Fab.

19. An agent obtained from the method of claim 14, which agent is capable of inhibiting the active site of Factor IX.

20. A method for inhibiting thrombosis in a patient whose blood is subjected to extracorporeal blood circulation which comprises contacting the extracorporeal circulating blood with an agent capable of inhibiting a step of the intrinsic pathway of coagulation in an amount effective to inhibit thrombosis in the patient.


21. The method of claim 20, wherein the agent is an active site-

-42-


blocked Factor XII compound.

22. The method of claim 20, wherein the agent is an active site-blocked Factor XI compound.


1/11

FIG. 1

2/11



3/11



4/11

FIG. 4A







FIG. 4B



5/11

FIG. 4C**FIG. 4D**

6/11

FIG. 4E





FIG. 5A

FIX deficient Plasma
+
Celite
↓ ∇

Human Plasma
+
Cephalin
+
CaCL
↓ ∇


Clot

FIG. 5B




8/11

FIG. 6A

Time to Hemostasis:


9/11

FIG 6B

Blood loss :


10/11

FIG. 7



11/11

FIG. 8



INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/08282

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :A61B 19/00

US CL :128/898

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 128/898

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, STN, DIALOG

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y,A	BENEDICT, et al. Active Site-blocked Factor IXA Prevents Intravascular Thrombus Formation in the Coronary Vasculature without Inhibiting Extravascular Coagulation in a Canine Thrombosis Model. The American Society for Clinical Investigation, Inc. Vol.88, November 1991, pages 1760-1765, see entire document.	1-22
Y,A	KUWABARA et al. Calreticulin, an Antithrombotic Agent Which Binds to Vitamin K-dependent Coagulation Factors, Stimulates Endothelial Nitric Oxide Production, and limits Thrombosis in Canine Coronary Arteries. The Journal of Biological Chemistry, Vol. 270, No.14, April 7, 1995, pages 8179-8187, see entire document.	1-22

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z*	document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means		
P document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

28 JULY 1997

Date of mailing of the international search report

29 AUG 1997

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

KELLY O'HARA

Telephone No. (703) 308-0780

INTERNATIONAL SEARCH REPORT**International application No.**
PCT/US97/08282**C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y,A	BERKOWITZ et al. Quantification of Contact System Activation Using a Radiometric Assay for Activated Factor IX, Department of Medicine, Mount Sinai School of Medicine New York, N.Y., March 1980, Vol.55, No.3, pages 528-531, see entire document.	1-22
Y,A	DIETRICH et al. Influence of High-Dose Aprotinin on Anticoagulation, Heparin Requirement, and Celite-and Kaolin-Activated Clotting Tie in Heparin-pretreated Patients Undergoing Open-Heart Surgery. Anesthesiology, Vol. 83, No. 4, October 1995, pages 679-689, see entire document.	1-22